Activating Innate & Adaptive Immunity to Fight Cancer

Oncovir, Inc is a pharmaceutical corporation dedicated to the development of nucleic-acid-based clinical therapies for cancer, infectious, immune, and degenerative disorders.

We promote Hiltonol® (poly-ICLC) as an experimental viral mimic and broad activator of innate and adaptive immunity. While initially developed as an interferon inducer, Hiltonol® has much broader biological effects in humans, including specific antiviral, immune activating, vaccine adjuvant, and antitumor actions. 

PICLC in PARKER Immunotherapy Clinical Trial for Prostate Cancer
Oncovir will collaborate in a metastatic prostate cancer study with the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute. This study is designed to evaluate multiple clinical hypotheses and mechanistically-defined combinations to evaluate the safety and efficacy of immunotherapy combinations in participants with mCRPC who have received prior secondary androgen receptor signaling inhibitor therapy (eg, abiraterone, enzalutamide, apalutamide).

© 2019 by Oncovir, Inc.    Terms of Use

  • Twitter